Increased Expression of Herpes Virus-Encoded hsv1-miR-H18 and hsv2-miR-H9-5p in Cancer-Containing Prostate Tissue Compared to That in Benign Prostate Hyperplasia Tissue

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.

Citation
Yun, S. J., P. Jeong, H. W. Kang, H. K. Shinn, Y. Kim, C. Yan, Y. Choi, et al. 2016. "Increased Expression of Herpes Virus-Encoded hsv1-miR-H18 and hsv2-miR-H9-5p in Cancer-Containing Prostate Tissue Compared to That in Benign Prostate Hyperplasia Tissue." International Neurourology Journal 20 (2): 122-130. doi:10.5213/inj.1632552.276. http://dx.doi.org/10.5213/inj.1632552.276.

Published Version
doi:10.5213/inj.1632552.276

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:27822070

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Increased Expression of Herpes Virus-Encoded hsv1-miR-H18 and hsv2-miR-H9-5p in Cancer-Containing Prostate Tissue Compared to That in Benign Prostate Hyperplasia Tissue

Seok Joong Yun1*, Pildu Jeong1*, Ho Won Kang1, Helen Ki Shinn2, Ye-Hwan Kim1, Chunri Yan1, Young-Ki Choi1, Dongho Kim1, Dong Hee Ryu1, Yun-Sok Ha3, Tae-Hwan Kim4, Tae Gyun Kwon4, Jung Min Kim5, Sang Heon Suh5, Seon-Kyu Kim5, Seon-Young Kim5, Sang Tae Kim9, Won Tae Kim1, Ok-Jun Lee11, Sung-Kwon Moon12, Nam-Hyung Kim13, Isaac Yi Kim14, Jayoung Kim15,16,17, Hee-Jae Cha18, Yung-Hyun Choi19, Eun-Jong Cha20, Wun-Jae Kim1

1Department of Urology, Chungbuk National University College of Medicine, Cheongju, Korea
2Department of Anesthesiology and Pain Medicine, Inha University College of Medicine, Incheon, Korea
3Department of Microbiology, College of Medicine and Medical Research Institute, Chungbuk National University, Cheongju, Korea
4Bio Medical Laboratories, Daejeon, Korea
5Department of Surgery, Chungbuk National University College of Medicine and Medical Research Institute, Cheongju, Korea
6Department of Urology, Kyungpook National University School of Medicine, Daegu, Korea
7NAR Center Inc., Daejeon Oriental Hospital of Daejeon University, Daejeon, Korea
8The Laboratory of Vascular Biology and Stem Cells, BioMedical Research Center, Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Korea
9Medical Genomics Research Center, Korean Bioinformation Center, Korea Research Institute of Bioscience and Biotechnology, Department of Functional Genomics, University of Science and Technology, Daejeon, Korea
10Biomedical Research Institute, Department of Neuropsychiatry, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seoul, Korea
11Department of Pathology, Chungbuk National University College of Medicine, Cheongju, Korea
12School of Food Science and Technology, Chung-Ang University, Anseong, Korea
13Department of Animal Sciences, Chungbuk National University, Cheongju, Korea
14The Section of Urologic Oncology and Dean and Betty Gallo Prostate Cancer Center, The Cancer Institute of New Jersey, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ, USA
15Department of Surgery, Harvard Medical School, Boston, MA, USA
16Division of Cancer Biology and Therapeutics, Departments of Surgery and Biomedical Sciences, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA
17Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA
18Department of Parasitology and Genetics, Kosis University College of Medicine, Busan, Korea
19Department of Biochemistry, Dongeui University College of Oriental Medicine, Busan, Korea
20Department of Biomedical Engineering, Chungbuk National University, Cheongju, Korea

*Seok Joong Yun and Pildu Jeong contributed equally to this study as co-first authors.

Submitted: February 26, 2016 / Accepted after revision: April 17, 2016

Copyright © 2016 Korean Continence Society

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION

Prostate cancer (CaP) is one of the most common malignancies in Western males, and the prevalence of CaP in Korean men is increasing [1,2]. Prostate infection and inflammation caused by bacteria and viruses are thought to be important drivers of carcinogenesis in CaP [3-5]. A meta-analysis investigating the relationship between sexually transmitted diseases (STDs) and the risk for CaP suggested that men with a history of infection with any STD or gonorrhea, specifically, exhibited increased risks of CaP (1.5 fold and 1.2 fold, respectively) [6]. However, the existence of a causal relation between inflammation from infection and prostate carcinogenesis is still debatable [3]. Several studies have suggested that viral microRNAs (miRNAs), mostly derived from herpes viruses, facilitate cross-talk between the virus and host during viral infection and pathogenesis [7,8]. For instance, viral miRNAs acting directly as oncogenes can be illustrated by the Kaposi's sarcoma-associated herpesvirus miR-K12-10 and miR-K12-12, both encoded within the transcript of the A isoform of kaposin, which is known to mediate cellular transformation through loss of growth control and cell surface-mediated inhibition [9]. Thus, a causal association between viral miRNAs and carcinogenesis should not be dismissed, even though evidence is limited.

Recently, we reported the presence of virus-encoded miRNAs in the urine of prostate cancer (CaP) patients. In this study, we investigated the expression of two herpes virus-encoded miRNAs in prostate tissue.

Purpose: Previously, we reported the presence of virus-encoded microRNAs (miRNAs) in the urine of prostate cancer (CaP) patients. In this study, we investigated the expression of two herpes virus-encoded miRNAs in prostate tissue.

Methods: A total of 175 tissue samples from noncancerous benign prostatic hyperplasia (BPH), 248 tissue samples from patients with CaP and BPH, and 50 samples from noncancerous surrounding tissues from these same patients were analyzed for the expression of two herpes virus-encoded miRNAs by real-time polymerase chain reaction (PCR) and immunocytochemistry using nanoparticles as molecular beacons.

Results: Real-time reverse transcription-PCR results revealed significantly higher expression of hsv1-miR-H18 and hsv2-miR-H9-5p in surrounding noncancerous and CaP tissues than that in BPH tissue (each comparison, P < 0.001). Of note, these miRNA were expressed equivalently in the CaP tissues and surrounding noncancerous tissues. Moreover, immunocytochemistry clearly demonstrated a significant enrichment of both hsv1-miR-H18 and hsv2-miR-H9 beacon-labeled cells in CaP and surrounding noncancerous tissue compared to that in BPH tissue (each comparison, P < 0.05 for hsv1-miR-H18 and hsv2-miR-H9).

Conclusions: These results suggest that increased expression of hsv1-miR-H18 and hsv2-miR-H95p might be associated with tumorigenesis in the prostate. Further studies will be required to elucidate the role of these miRNAs with respect to CaP and herpes viral infections.

Keywords: MicroRNAs; Prostate Neoplasms; Herpesviridae; Prostate Hyperplasia

**Fund/Grant Support:** This research was supported by the Functional Districts of the Science Belt support program (No. 2015K000284), and the National Research Foundation of Korea (No. NRF-2014R1A2A1A090006983, NRF-2014R1A2A2A04007036, and NRF-2015R1A2A2A03004100) of Ministry of Science, ICT and Future Planning.

**Research Ethics:** The collection and analysis of all samples was approved by the Institutional Review Board of Chungbuk National University, and written informed consent was obtained from each subject (approval numbers: 2006-01-001 and GR2010-12-010).

**Conflict of Interest:** No potential conflict of interest relevant to this article was reported.
H9-5p, was compared in BPH tissue, cancer tissue, and surrounding noncancerous tissue, and their association with pathological outcomes was investigated.

**MATERIALS AND METHODS**

**Cases and Controls**

For this study, a total of 175 samples from noncancerous BPH tissues, 50 samples from noncancerous surrounding tissues, and 248 samples from cancerous tissues were obtained from patients with CaP and BPH at Chungbuk National University Hospital (Table 1). A schematic of the study design, which included three different cohorts, is shown in Fig. 1. All tissues were harvested from patients with CaP who underwent radical prostatectomy or palliative transurethral resection (TUR), or patients with BPH who underwent TUR. Tissue samples were macrodissected within 15 minutes of surgical resection. Each prostate specimen was confirmed by analysis of fresh-frozen sections, and the remaining tissue was frozen in liquid nitrogen and stored at −80°C until use. BPH controls with serum PSA levels ≥ 3 ng/mL underwent transrectal prostate biopsy prior to TUR to rule out the presence of cancer. Patients receiving neoadjuvant therapies, such as androgen deprivation or radiation therapy, were excluded from the study. Gleason grades were assigned to specimens obtained from 12-core transrectal biopsies, transurethral resection of the prostate or radical prostatectomy.

**Table 1.** Clinical characteristics of the patients and controls

| Characteristic | BPH and prostate cancer tissues | BPH, surrounding noncancerous, and prostate cancer tissues | Direct staining |
|---------------|-------------------------------|----------------------------------------------------------|----------------|
|               | Control | Case | Control | Case | Control | Case |
| No.           | 131     | 192  | 37      | 41   | 7       | 24   |
| Age (yr)      | 71.5 (46–89) | 69.1 (50–92) | 71.6 (58–34) | 69.2 (58–80) | 73.6 (68–80) | 68.9 (65–73) |
| PSA (ng/mL)   | 4.9 ± 4.4 | 143.0 ± 584.5 | 4.3 ± 4.9 | 14.9 ± 15.9 | 11.7 ± 9.0 | 37.3 ± 87.2 |
| Operation (%) | -       | 135 (70.3) | - | 41 (100) | 7 (100) | - |
| TURP          | 131 (100) | 57 (29.7) | - | 135 (70.3) | 7 (100) | - |
| Radical prostatectomy | -      | 135 (70.3) | - | 41 (100) | 7 (100) | - |
| Gleason score (%) | 7 (3.6) | - | 6 (14.6) | - | 0 (0) | - |
| ≤ 6           | -       | 7 (3.6) | - | 6 (14.6) | - | 0 (0) |
| 7             | -       | 96 (50.0) | - | 24 (58.5) | - | 15 (62.5) |
| 8             | -       | 34 (17.7) | - | 7 (17.0) | - | 3 (12.5) |
| 9             | -       | 49 (25.5) | - | 3 (7.3) | - | 6 (25) |
| 10            | -       | 6 (3.1) | - | 1 (2.4) | - | 0 (0) |
| TNM stage     | 136 (65.6) | 41 (100) | 21 (87.5) | 3 (12.5) |
| T3 or less    | 126 (65.6) | 41 (100) | 21 (87.5) | 3 (12.5) |
| T4 or metastatic | 66 (34.4) | - | - | - |

Values are presented as median (range), mean ± standard deviation, or number (%).

BPH, benign prostatic hyperplasia; PSA, prostate-specific antigen; TURP, transurethral resection of the prostate.
Tumor stage was estimated from specimens obtained by radical prostatectomy, or from computed tomography, magnetic resonance imaging, or bone scans. The collection and analysis of all samples was approved by the Institutional Review Board of Chungbuk National University, and written informed consent was obtained from each subject (approval numbers: 2006-01-001 and GR2010-12-010). Gleason grades and TNM 2002 staging were used as prognostic factors.

Purification of miRNA
Total miRNAs were isolated from 1 mg of each tissue specimen using the Genolution miRNA Purification Kit (Genolution Pharmaceuticals Inc., Seoul, Korea). Reverse transcription of miRNA was conducted with the miScript Reverse Transcription Kit (Qiagen Korea, Seoul, Korea) according to the manufacturer's recommended protocol.

Amplification of miRNA by Real-Time PCR
To quantify miRNA expression, real-time polymerase chain reaction (PCR) amplification was performed using a Rotor-Gene Q (Qiagen, Valencia, CA, USA) and the miScript PCR Starter Kit (Qiagen Korea). Chemically synthesized RNA oligonucleotides (Cosmogenetech, Seoul, Korea) corresponding to the target miRNAs were used to generate standard curves. The standard curves ranged from 30 to 3 × 10^4 copies. The target miRNAs (hsv1-miR-H18 and hsv2-miR-H9-5p) were amplified using primers CCCGCCGCCGCCGACCGGCAGGACC and CTGGAGGTTGGATGTCGGGTG, respectively. The conditions used for real-time PCR are described in the manufacturer's protocol. All samples were tested in triplicate.

Preparation of QD565/QD525 Nanoparticle-Conjugated hsv1-miR-H18 and hsv2-miR-H9-Responsive Molecular Beacons
QD565-hsv1-miR-H18 and QD525-hsv2-miR-H9 beacons specific for hsv1-miR-H18 and hsv2-miR-H9 were prepared as previously described [11]. The sequences of the hsv1-miR-H18 and hsv2-miR-H9 beacon and the control scrambled beacon were as follows: 5′-NH2-TTGGCGGTGTCGCGGCTCGCCGCGC-GGG-CGCGGCCGACCACAGCC-BHQ2-3′, 5′-NH2-TTCGCGGTGTCGCGGCTCGCCGCGC-GGG-CGCGGCCGACCACAGCC-BHQ2-3′, and 5′-NH2-TTGGCGGTGTCGCGGCTCGCCGCGC-GGG-CGCGGCCGACCACAGCC-BHQ2-3′, respectively. The carboxyl quantum dot (QD) nanoparticles (Life Technologies Inc., Eugene, CA, USA) were prepared as previously described [12] and then covalently conjugated to the hsv1-miR-H18 and hsv2-miR-H9 beacons (10 pM) by incubation for 1 hour at room temperature. N-ethyl-N′-dimethylaminopropyl carbodiimide was used to increase the coupling efficiency between the amine and carboxyl groups.

Confocal Microscopy of QD565 Particles Within Tissues
Tissues were examined by whole-mount immunocytochemistry as previously described [13]. The QD565-hsv1-miR-H18/hsv2-miR-H9 beacons were used as follows for detection: QD565-hsv1-miR-H18 beacon and QD525-hsv2-miR-H9 beacons, and hsv-miR-HS beacon probes (1:1,000; Bioneer, Daejeon, Korea). Excitation was provided by a He/Ne laser (wavelengths, 405 nm and 543 nm) and images of selected tissues were visualized using the 4× and 20× objectives of a scanning Zeiss LSM 710 confocal microscope (Carl Zeiss, Oberkochen, Germany) with an Axiovert 200 M. After scanning specific regions to determine the tissue distribution using the region of interest scan feature of Zen 2011 software (Carl Zeiss MicroImaging GmbH, Jena, Germany), a virtual mask was drawn within the selected tissue area for a 5×5 tile scan area. Individual tissues were imaged using a 5×5 tile scan area with tile scan sections.

Statistical Analyses
Nonparametric tests were used to compare expression of the two miRNAs between groups, because data could not always be transformed to achieve normality. Receiver operating characteristic (ROC) curves were used to evaluate the difference in expression of the two miRNAs in cancer tissues and BPH control tissues. Spearman correlation coefficient (r) was used to evaluate the correlation between miRNAs in surrounding noncancerous tissue with that in matched CaP tissues. Statistical analyses was performed using IBM SPSS Statistics ver. 21.0 (IBM Co., Armonk, NY, USA), and P < 0.05 was considered statistically significant.

RESULTS
Expression of hsv1-miR-H18 and hsv2-miR-H9-5p in CaP
To investigate the potential association of two viral hsv1-miR-H18 and hsv2-miR-H9-5p miRNAs with clinicopathological outcomes, the expression of these miRNAs in BPH tissue, cancer tissue, and noncancerous surrounding tissues was compared. Real-time PCR results revealed increased expression of hsv1-miR-H18 and hsv2-miR-H9-5p in CaP tissue compared to that in BPH tissue (each P < 0.001) (Fig. 2). To confirm the
specificity of the real-time PCR, PCR products were cloned into TA cloning vectors, and miRNAs from at least 20 clones were sequenced. Results showed 100% identity between the hsv1-miR-H18 and hsv2-miR-H9-5p clone, while no human homologs were detected in GenBank.

To determine whether this analysis might be used as a diagnostic tool, an ROC analysis was performed to assess how well hsv1-miR-H18 and hsv2-miR-H9-5p expression levels segregate patients with CaP from BPH controls. The areas under the receiver operating characteristic (AUC) curves for hsv1-miR-H18 and hsv2-miR-H9-5p were 0.914 and 0.916, respectively, indicating high sensitivity and specificity. There was no significant difference in the expression levels of the 2 miRNAs and or pathological characteristics between the groups, however (i.e., PSA ≤ 10 ng/mL vs. > 10 ng/mL; Gleason score ≤ 7 vs. ≥ 8; and ≤ T3 vs. T4 or metastasis) (Table 2). This indicates these miRNAs may be a useful tool to identify patients with CaP, even though their expression levels do not correlate with disease severity.

Expression of hsv1-miR-H18 and hsv2-miR-H9-5p in BPH Tissue, CaP Tissue, and Surrounding Noncancerous Tissue

Both hsv1-miR-H18 and hsv2-miR-H9-5p were found to be expressed more highly in CaP tissue and surrounding noncancerous tissue than in BPH tissue (each P < 0.001) (Fig. 3). This
indicates that these miRNAs are highly expressed throughout the prostate when a tumor is present, and that their expression is lower in noncancerous prostate tissues. In addition, miRNA expression in surrounding noncancerous tissues significantly correlated with that of the matched CaP tissue (Spearmans correlation r = 0.317 and P = 0.044 for hsv1-miR-H18, and r = 0.759 and P < 0.001 for hsv2-miR-H9-5p).

**Direct Staining of miRNAs in BPH, CaP, and Noncancerous Tissues**

A specific QD<sub>565</sub>-hsv1-miR-H18 and hsv2-miR-H9 beacon detection system was used to stain the two miRNAs in prostate

**Table 2. Expression of hsv1-miR-H18 and hsv2-miR-H9-5p in prostate cancer**

| Variable          | No. of patients | hsv1-miR-H18 level (×10<sup>3</sup> copies/miRNA concentration) | P-value | hsv2-miR-H9-5p level (×10<sup>3</sup> copies/miRNA concentration) | P-value |
|-------------------|-----------------|---------------------------------------------------------------|---------|-----------------------------------------------------------------|---------|
| Age (yr)          |                 |                                                               |         |                                                                |         |
| < 70              | 101             | 280.4 (58.8–4064.8)                                           | 0.495   | 38.3 (14.5–136.8)                                               | 0.412   |
| ≥ 70              | 91              | 293.6 (45.2–2043.7)                                           |         | 31.0 (15.0–114.2)                                               |         |
| PSA (ng/mL)       |                 |                                                               |         |                                                                |         |
| < 10              | 78              | 355.0 (53.5–3913.2)                                           | 0.465   | 49.8 (17.6–142.0)                                               | 0.079   |
| ≥ 10              | 114             | 255.5 (45.9–2374.4)                                           |         | 31.1 (12.5–113.7)                                               |         |
| Gleason score     |                 |                                                               |         |                                                                |         |
| ≤ 7               | 103             | 295.0 (62.8–4685.8)                                           | 0.297   | 39.3 (16.3–136.3)                                               | 0.195   |
| ≥ 8               | 89              | 286.1 (38.8–2429.6)                                           |         | 28.1 (12.7–110.4)                                               |         |
| Stage             |                 |                                                               |         |                                                                |         |
| T3 or less        | 126             | 305.0 (60.0–3290.7)                                           | 0.198   | 35.3 (16.8–135.1)                                               | 0.241   |
| T4 or metastatic  | 66              | 257.0 (35.0–1721.1)                                           |         | 30.4 (11.2–104.2)                                               |         |

Values are presented as median (interquartile range).
PSA, prostate-specific antigen.
The Mann-Whitney U-test was used to compare expression levels and clinical variables.
There was an increase in fluorescence in both CaP and surrounding noncancerous tissues compared to that in BPH tissues (P < 0.05 for hsv1-miR-H18 and hsv2-miR-H9), confirming the findings from the real-time PCR analysis. Further, the staining patterns of the two herpes-encoded miRNAs were quite similar, with strong cytoplasmic staining and
increased staining in the epithelial layer compared to that in the stroma. Interestingly, luminal cells, which have direct contact with seminal fluid, showed the strongest fluorescence intensity.

**DISCUSSION**

Here, we show that the expression levels of hsv1-miR-H18 and hsv2-miR-H9-5p were higher in CaP and surrounding noncancerous tissue than in BPH tissues. This suggests that these 2 miRNAs may be specific biomarkers for tumor-containing organs, as opposed to cancer-specific markers. These findings may be clinically important, suggesting it may be possible to detect early tumorigenesis before the cancerous tissue comprises a large portion of the prostate. The ability to diagnosis cancer while the disease is still localized within the originating organ has important implications, including increased likelihood of curative resection. Numerous previous studies have focused on the identification of cancer-specific biomarkers for CaP; however, when the disease is localized, the sensitivity and specificity of biomarker detection in body fluids is very low. PSA is a prostate-specific marker that can be detected in patient serum, and although it is considered an outstanding marker for detecting CaP, it is not a cancer-specific marker, and so patients are often subjected to the painful transrectal biopsy procedure in order to rule out cancer. In this study, we evaluated two herpes virus-encoded miRNAs as organ-specific markers of cancer. We found that the expression levels of hsv1-miR-H18 and hsv2-miR-H9-5p were significantly higher in CaP tissue and the surrounding noncancerous tissue than in BPH tissue (each comparison, P < 0.0001). Further, these results may explain why the miRNAs were easily detected in urine samples of patients with CaP [10].

Since the discovery of viral miRNAs in human tissues [14], many researchers have focused on identifying the functions and roles of these molecules in human cells; however, such research is still in its initial stages. While certain viral miRNAs are thought to enable viruses to evade the host immune system [8], to our knowledge, the direct relationship between virus-encoded miRNAs and initiation, progression, and metastasis of CaP has not been studied. Recent evidence suggests that CaP is associated with infection and inflammation caused by bacteria and viruses [3-5]. Therefore, it is possible that hsv1-miR-H18 and hsv2-miR-H9-5p play a role in CaP carcinogenesis, a finding that would be supported by our real-time PCR results. Future studies will be required to address this possibility.

One of the major risk factors for CaP is sexually transmitted infections (STIs). Given the solid evidence that human papillomavirus is the major causative agent of cervical cancer [15], it has been hypothesized that STIs such as those caused by Neisseria gonorrhoeae, Treponema pallidum, Chlamydia trachomatis, Trichomonas vaginalis, and herpes viruses may be associated with carcinogenesis of the prostate. While bacterial infections are also thought to cause inflammation and atrophy of the prostate, viral infections, and herpes viruses in particular, can lead to the transformation of prostate epithelial cells [16]. Several epidemiologic studies have suggested possible associations between STIs and CaP [17-19], but the data are inconsistent. A recent meta-analysis suggested that herpes virus type 2 infection is associated with an increased risk of CaP (odds ratio, 1.209; 95% confidence interval [CI], 1.003–1.456) [20]. However, another meta-analysis showed that men who reported never having had an STI were at increased risk for CaP (summary relative risk [SRR], 1.49; 95% CI, 1.19–1.92), and that men with gonorrheal infection also showed an increased risk of CaP (SRR, 1.20; 95% CI, 1.05–1.37) [6]. However, no single STI, including herpes virus, has been definitively linked to CaP [6]. These conflicting findings may be a result of different methods used to detect antibodies against STI-causing agents in serum. Therefore, further well-designed investigations are needed to elucidate the potential links between STIs and increased risk of CaP.

Because the prostate is not a target organ for herpes virus replication, it is possible that the presence of herpes virus-encoded miRNAs in CaP tissues and urine might not be linked to herpes infection of the prostate. However, given that there are no human homologs of either hsv1-miR-H18 or hsv2-miR-H9-5p, and that other herpes-encoded miRNAs (e.g., hsv1-miR-H13, hsv2-miR-H2, and hsv2-miR-H7) are also enriched in CaP tissues (data not shown), it is difficult to rule out a direct association between herpes infection, with the subsequent presence of virus-encoded miRNAs, and CaP development. Therefore, the findings presented herein may provide the missing link between herpes virus infection and carcinogenesis of the prostate, and support the theory that STIs are a major risk factor for CaP.

Our study had several inherent weaknesses. First, anatomical differences in the expression of the 2 virus-encoded miRNAs were not considered, even though BPH originates from the transitional zone, while CaP is usually from the peripheral zone. Second, we did not find any direct evidence of the source of these virus-encoded miRNAs. Further studies are needed to investigate the origin of these miRNAs. Lastly, because we did...
not perform an in vitro experiment, the influence of these miRNAs on CaP cells is uncertain.

In conclusion, there is increased expression of hsv1-miR-H18 and hsv2-miR-H9-5p in CaP and surrounding noncancerous tissues compared to that in BPH tissues, suggesting that herpes virus-encoded miRNAs might be associated with tumorigenesis in the prostate. Further investigation will be required in order to elucidate the role of these miRNAs in relation to herpes viral infection as well as CaP, and to confirm their validity as biomarkers.

REFERENCES

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Jung KW, Won YJ, Park S, Kong HJ, Sung J, Shin HR, et al. Cancer statistics in Korea: incidence, mortality and survival in 2005. J Korean Med Sci 2009;24:995-1003.
3. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007;7:256-69.
4. Sfanos KS, Isaacs WB, De Marzo AM. Infections and inflammation in prostate cancer. Am J Clin Exp Urol 2013;1:3-11.
5. Kwon OJ, Zhang L, Ittmann MM, Xin L. Prostatic inflammation enhances basal-to-luminal differentiation and accelerates initiation of prostate cancer with a basal cell origin. Proc Natl Acad Sci U S A 2014;111:E592-600.
6. Caini S, Gandini S, Dudas M, Bremer V, Severi E, Gherasim A. Sexually transmitted infections and prostate cancer risk: a systematic review and meta-analysis. Cancer Epidemiol 2014;38:329-38.
7. Pfeffer S, Sewer A, Lagos-Quintana M, Sheridan R, Sander C, Grässer FA, et al. Identification of microRNAs of the herpesvirus family. Nat Methods 2005;2:269-76.
8. Veksler-Lublinsky I, Shemer-Avni Y, kedem K, Ziv-Ukelson M. Gene bi-targeting by viral and human miRNAs. BMC Bioinformatics 2010;11:249.
9. Kliche S, Nagel W, Kremmer E, Atzler C, Ege A, Knorr T, et al. Signaling by human herpesvirus 8 kaposin A through direct membrane recruitment of cytohesin-1. Mol Cell 2001;7:833-43.
10. Yun SJ, Jeong P, Kang HW, Kim YH, Kim EA, Yang C, et al. Urinary microRNAs of prostate cancer: virus-encoded hsv1-miRH18 and hsv2-miR-H9-5p could be valuable diagnostic markers. Int Neurourol J 2015;19:74-84.
11. Yoon TJ, Yu KN, Kim E, Kim JS, Kim BG, Yun SH, et al. Specific targeting, cell sorting, and bioimaging with smart magnetic silica core-shell nanomaterials. Small 2006;2:209-15.
12. So MK, Loening AM, Gambhir SS, Rao J. Creating self-illuminating quantum dot conjugates. Nat Protoc 2006;1:1160-4.
13. He S, Krens SG, Zhan H, Gong Z, Hogendoorn PC, Spaink HP, et al. A ΔRaf1-ER-inducible oncogenic zebrafish liver cell model identifies hepatocellular carcinoma signatures. J Pathol 2011;225:19-28.
14. Pfeffer S, Zavolan M, Grasser FA, Chien M, Russo JJ, Ju J, et al. Identification of virus-encoded microRNAs. Science 2004;304:734-6.
15. Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008;26 Suppl 10:K1-16.
16. Sutcliffe S. Sexually transmitted infections and risk of prostate cancer: review of historical and emerging hypotheses. Future Oncol 2010;6:1289-311.
17. Haid M, Sharon N. Immunofluorescent evidence of prior herpes simplex virus type-2 infection in prostate carcinoma. Urology 1984;24:623-5.
18. Dennis LK, Coughlin JA, McKinnon BC, Wells TS, Gaydos CA, Hansmikova E, et al. Sexually transmitted infections and prostate cancer among men in the U.S. military. Cancer Epidemiol Biomarkers Prev 2009;18:2665-71.
19. Sutcliffe S, Giovannucci E, Gaydos CA, Viscidi RP, Jenkins FJ, Zelnikman JM, et al. Plasma antibodies against Chlamydia trachomatis, human papillomavirus, and human herpesvirus type 8 in relation to prostate cancer: a prospective study. Cancer Epidemiol Biomarkers Prev 2007;16:1573-80.
20. Ge X, Wang X, Shen P. Herpes simplex virus type 2 or human herpesvirus 8 infection and prostate cancer risk: a meta-analysis. Biomed Rep 2013;1:433-9.